IMPORTANT INFORMATION FOR PRIVATE INVESTORS

Our investments place your capital at risk. We do not provide investment, tax or legal advice and we recommend you seek professional advice if you are considering investing with us. You may lose part or all of the amount you invest with us. We invest in unquoted shares in small companies. The value of these shares can be volatile, and the shares are often difficult to sell. The tax reliefs associated with our investments depend on the individual circumstances of each investor and may be subject to change. Past performance is not a reliable indicator of future results. Our forecasts and performance targets cannot accurately predict how investments will perform.

ACCEPT DECLINE
Change Visitor Type Sign up to our newsletter

Oxford BioTherapeutics and Kite establish cell therapy research collaboration

This article will open in a new window.Oxford Capital is not responsible for the content of third-party websites. Would you like to continue?

YesNo

Oxford BioTherapeutics and Kite establish cell therapy research collaboration

By Oxford Capital |

Positive news for our portfolio company, Oxford BioTherapeutics, it has announced a research collaboration with Kite, the global leader in cell therapy to evaluate five novel targets for a number of hematologic and solid tumor indications.

All News

Awards

  • BEST EIS
    FUND MANAGER    2013,2012,2010 AND 2006

  • VENTURE CAPITAL
    HOUSE OF THE YEAR    WINNER 2013 AND 2005

  • INVESTOR OF
    THE YEAR    WINNER IN 2012 AND 2013

  • MOST IMPACTFUL
    INVESTMENT    WINNER 2017

  • BEST ANGEL
    SYNDICATE    WINNER 2018

  • BVCA Excellence in ESG
    GP CATEGORY    COMMENDED 2020

  • VC INVESTOR OF THE YEAR
    GIANT HEALTH AWARDS    WINNER 2020

  • EXIT OF THE YEAR
    ONE TO WATCH    2020